Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2012 (2012), Article ID 580437, 6 pages
http://dx.doi.org/10.1155/2012/580437
Research Article

Meta-Analysis of Randomized Controlled Trials on Androgens versus Erythropoietin for Anaemia of Chronic Kidney Disease: Implications for Developing Countries

1Nephrology Unit, Department of Medicine, Bayero University, Kano, PMB 3452, Nigeria
2Usmanu Danfodiyo University, Sokoto, PMB 2346, Nigeria
3Mayo Clinic College of Medicine, Rochester, MN 55905, USA
4King Fahad Medical City, Riyadh 11525, Saudi Arabia

Received 25 February 2012; Revised 28 August 2012; Accepted 2 September 2012

Academic Editor: Li-Li Hsiao

Copyright © 2012 B. Adamu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. M. Clement, S. Klarenbach, M. Tonelli, N. Wiebe, B. Hemmelgarn, and B. J. Manns, “An economic evaluation of erythropoiesis-stimulating agents in CKD,” American Journal of Kidney Diseases, vol. 56, no. 6, pp. 1050–1061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. Maïz, E. Abderrahim, and K. Zouaghi, “Anemia and end-stage renal disease in the developing world,” Artificial Organs, vol. 26, no. 9, pp. 760–764, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. C. Cattran, S. S. A. Fenton, and D. R. Wilson, “A controlled trial of nandrolone decanoate in the treatment of uremic anemia,” Kidney International, vol. 12, no. 6, pp. 430–437, 1977. View at Google Scholar · View at Scopus
  4. J. F. Navarro, C. Mora, M. Macía, and J. García, “Randomized prospective comparison between erythropoietin and androgens in CAPD patients,” Kidney International, vol. 61, no. 4, pp. 1537–1544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Gascon, J. J. Belvis, F. Berisa, E. Iglesias, V. Estopinan, and J. L. Teruel, “Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis,” Geriatric Nephrology and Urology, vol. 9, no. 2, pp. 67–72, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. H. K. Aggarwal, R. Sehgal, S. Singh, N. Nand, K. Bharti, and D. Chakrabarti, “Evaluation of efficacy of low dose recombinant human erythropoietin in combination with androgen therapy in anaemia of chronic renal failure,” Journal, Indian Academy of Clinical Medicine, vol. 6, no. 3, pp. 208–215, 2005. View at Google Scholar · View at Scopus
  7. N. P. Singh, A. Ganguli, and T. Singh, “A comparative study of nandrolone decanoate versus recombinant human erythropoietin on anemia in Indian pre-dialysis chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 18, supplement 4, pp. 692–693, 2003. View at Google Scholar
  8. A. Levin, “Prevalence of cardiovascular damage in early renal disease,” Nephrology Dialysis Transplantation, vol. 16, no. 2, pp. 7–11, 2001. View at Google Scholar · View at Scopus
  9. F. Locatelli, R. L. Pisoni, T. Akizawa et al., “Anemia management for hemodialysis patients: kidney disease outcomes quality initiative (K/DOQI) guidelines and dialysis outcomes and practice patterns study (DOPPS) findings,” American Journal of Kidney Diseases, vol. 44, no. 5, supplement 2, pp. S27–S33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. E. F. Unger, A. M. Thompson, M. J. Blank, and R. Temple, “Erythropoiesis-stimulating agents-time for a reevaluation,” New England Journal of Medicine, vol. 362, no. 3, pp. 189–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Gordon, E. D. Zanjani, R. D. Levere, and A. Kappas, “Stimulation of mammalian erythropoiesis by 5beta-H steroid metabolites.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 65, no. 4, pp. 919–924, 1970. View at Google Scholar · View at Scopus
  12. C. A. Johnson, “Use of androgens in patients with renal failure,” Seminars in Dialysis, vol. 13, no. 1, pp. 36–39, 2000. View at Google Scholar · View at Scopus
  13. L. R. Solomon and E. D. Hendler, “Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics,” Acta Haematologica, vol. 79, no. 1, pp. 12–19, 1988. View at Google Scholar · View at Scopus
  14. “Recommendations on testing for funnel plot asymmetry,” in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, J. P. T. Higgins and S. Green, Eds., The Cochrane Collaboration, Queensland, Australia, 2011.
  15. J. Lau, J. P. A. Ioannidis, N. Terrin, C. H. Schmid, and I. Olkin, “The case of the misleading funnel plot,” British Medical Journal, vol. 333, no. 7568, pp. 597–600, 2006. View at Google Scholar · View at Scopus
  16. J. L. Teruel, R. Marcen, J. Navarro-Antolin, A. Aguilera, G. Fernandez-Juarez, and J. Ortuño, “Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study,” Journal of the American Society of Nephrology, vol. 7, no. 1, pp. 140–144, 1996. View at Google Scholar · View at Scopus
  17. A. K. Paul, Z. A. Latif, S. Iqbal, F. Amin, S. M. Shefin, and S. M. Ashrafuzzaman, “Androgen versus erythropoietin for the treatment of anaemia of pre-dialysis chronic kidney disease,” Mymensingh Medical Journal, vol. 21, no. 1, pp. 125–128, 2012. View at Google Scholar
  18. S. Eiam-Ong, S. Buranaosot, S. Eiam-Ong, A. Wathanavaha, and P. Pansin, “Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease,” Journal of Renal Nutrition, vol. 17, no. 3, pp. 173–178, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Lee, S. H. Ahn, and J. H. Song, “Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin.,” Korean Journal of Internal Medicine, vol. 17, no. 3, pp. 167–173, 2002. View at Google Scholar · View at Scopus
  20. W. J. Gaughan, K. A. Liss, S. R. Dunn et al., “A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients,” American Journal of Kidney Diseases, vol. 30, no. 4, pp. 495–500, 1997. View at Google Scholar · View at Scopus
  21. M. D. Sánchez de la Nieta, G. Caparrós, and F. Rivera, “Epoetin-induced pure red cell aplasia successfully treated with androgens,” Journal of Nephrology, vol. 19, no. 2, pp. 220–221, 2006. View at Google Scholar · View at Scopus
  22. X. Tang, R. Gu, X. S. Xie, and T. Wu, “Androgens for the anaemia of chronic kidney disease in adults (Protocol),” Cochrane Database of Systematic Reviews. In press. View at Publisher · View at Google Scholar · View at Scopus